- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 third quarter ended June 30, 2014, on Tuesday, August 12, 2014, at 4:30 p.m. EDT. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 82825377. Investors may also access a live audio webcast of this conference call on the Company's website at www.arrowheadresearch.com/presentations.
A replay of the webcast will be available approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 7 days. The audio replay can be accessed by dialing 855-859-2056 (toll free from the US), or 404-537-3406 (for international callers) and entering Conference ID 82825377.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.
For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to .
For more information, please click here
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Martina Schwarzkopf, Ph.D.
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016